Onxeo has engaged MCT (Regional CRO specialized on Middle East and Africa) to expand “Relieve” phase III HCC study in 3 Middle East countries (Lebanon, Egypt and Saudi Arabia). More information in Onxeo press release: 150326EN_Livatag
Related Posts
Marwan Felaefel speaker at PRIM&R – AER conference in Boston on Nov 12-Nov15
News / November 18, 2015
MCT at CardioVascular Clinical Trialist forum
News / September 20, 2019

